Show simple item record

dc.contributor.authorNewhouse, Paul A.
dc.contributor.authorAlbert, Kimberly
dc.contributor.authorAstur, Robert
dc.contributor.authorJohnson, Julia V.
dc.contributor.authorNaylor, Magdalena R.
dc.contributor.authorDumas, Julie A.
dc.date2022-08-11T08:11:05.000
dc.date.accessioned2022-08-23T17:32:43Z
dc.date.available2022-08-23T17:32:43Z
dc.date.issued2013-12-01
dc.date.submitted2014-01-27
dc.identifier.citation<p>Newhouse P, Albert K, Astur R, Johnson J, Naylor M, Dumas J. Tamoxifen improves cholinergically modulated cognitive performance in postmenopausal women. Neuropsychopharmacology. 2013 Dec;38(13):2632-43. doi: 10.1038/npp.2013.172. <a href="http://dx.doi.org/10.1038/npp.2013.172" target="_blank">Link to article on publisher's site</a></p>
dc.identifier.issn0006-3223 (Linking)
dc.identifier.doi10.1038/npp.2013.172
dc.identifier.pmid23867982
dc.identifier.urihttp://hdl.handle.net/20.500.14038/51011
dc.description.abstractTamoxifen (TMX) is a selective estrogen receptor modulator that is used as an estrogen receptor antagonist for the treatment and prevention of breast cancer. Whether TMX has antagonist activities in the human brain is less clear and its effects on cognitive function have not been experimentally explored. This study examined how TMX affected cognitive performance in older women using a model of anticholinergic drug-induced cognitive dysfunction. Twenty-one postmenopausal women were administered 20 mg of oral TMX or placebo for 3 months. Participants then took part in five drug challenges using the anticholinergic antinicotinic agent mecamylamine (MECA) and antimuscarinic agent scopolamine (SCOP) and were tested on a comprehensive battery including tasks of attention and psychomotor function, verbal episodic memory, and spatial navigation. After a 3-month placebo washout, participants were then crossed over to the alternate treatment and repeated the drug challenges after 3 months. Compared with placebo treatment, TMX significantly attenuated the impairment from cholinergic blockade on tasks of verbal episodic memory and spatial navigation, but effects on attentional/psychomotor tasks were more variable. Analysis by APOE genotype showed that APO varepsilon4+ women showed a greater beneficial effect of TMX on reversing the cholinergic impairment than APO varepsilon4- women on most tasks. This study provides evidence that TMX may act as an estrogen-like agonist to enhance cholinergic system activity and hippocampally mediated learning.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=23867982&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828534/
dc.subjectacetylcholine
dc.subjectcognition
dc.subjectmenopause
dc.subjectmecamylamine
dc.subjectscopolamine
dc.subjecttamoxifen
dc.subjectCognitive Neuroscience
dc.subjectMedical Neurobiology
dc.subjectObstetrics and Gynecology
dc.subjectPsychiatry and Psychology
dc.subjectWomen's Health
dc.titleTamoxifen improves cholinergically modulated cognitive performance in postmenopausal women
dc.typeJournal Article
dc.source.journaltitleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
dc.source.volume38
dc.source.issue13
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/wfc_pp/546
dc.identifier.contextkey5022267
html.description.abstract<p>Tamoxifen (TMX) is a selective estrogen receptor modulator that is used as an estrogen receptor antagonist for the treatment and prevention of breast cancer. Whether TMX has antagonist activities in the human brain is less clear and its effects on cognitive function have not been experimentally explored. This study examined how TMX affected cognitive performance in older women using a model of anticholinergic drug-induced cognitive dysfunction. Twenty-one postmenopausal women were administered 20 mg of oral TMX or placebo for 3 months. Participants then took part in five drug challenges using the anticholinergic antinicotinic agent mecamylamine (MECA) and antimuscarinic agent scopolamine (SCOP) and were tested on a comprehensive battery including tasks of attention and psychomotor function, verbal episodic memory, and spatial navigation. After a 3-month placebo washout, participants were then crossed over to the alternate treatment and repeated the drug challenges after 3 months. Compared with placebo treatment, TMX significantly attenuated the impairment from cholinergic blockade on tasks of verbal episodic memory and spatial navigation, but effects on attentional/psychomotor tasks were more variable. Analysis by APOE genotype showed that APO varepsilon4+ women showed a greater beneficial effect of TMX on reversing the cholinergic impairment than APO varepsilon4- women on most tasks. This study provides evidence that TMX may act as an estrogen-like agonist to enhance cholinergic system activity and hippocampally mediated learning.</p>
dc.identifier.submissionpathwfc_pp/546
dc.contributor.departmentDepartment of Obstetrics and Gynecology
dc.source.pages2632-43


This item appears in the following Collection(s)

Show simple item record